Advertisement
Home »

STEP-HFpEF DM: Semaglutide Beneficial for Patients With HFpEF and T2D

Apr 18, 2024

REFERENCES & ADDITIONAL READING

Kosiborod M. Once-weekly semaglutide in patients with heart failure with preserved ejection fraction, obesity and type 2 diabetes: main results from the Step-HFpEF DM trial. FCR 1, Session 403. Presented at: ACC 2024 Scientific Session, 6–8 April 6-8, 2024, Atlanta, GA.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement